DeadlineHigh Impact
California Delete Act creates DROP deletion mechanism for data brokers
California's Delete Act requires data brokers to participate in the Data Broker Requests and Opt-Out Platform, with deletion-processing obligations beginning in 2026.
Operator impact: Clinic lead vendors, list brokers, enrichment providers, data brokers, and agencies should review whether patient-adjacent lead data, health-interest segments, and retargeting audiences create data broker compliance exposure.
Effective Jan 1, 2026
Deadline Aug 1, 2026
EffectiveHigh Impact
California Medical Board states med spas offering medical procedures must be physician-owned
California Medical Board guidance states medical spas are marketing vehicles for medical procedures and, if offering medical procedures, must be owned by physicians.
Operator impact: California med spa founders, MSOs, investors, injectors, and marketing partners should review ownership, physician control, management-service agreements, advertising, medical decision-making, and non-physician financial control points.
ProposedHigh Impact
California AB 1990 would add GLP-1 compounding quality-control requirements
California AB 1990 would require bulk drug substances used in compounded GLP-1 medications to be pharmaceutical grade, compliant with federal standards, quality-control tested, and supported by certificates of analysis and records.
Operator impact: California clinics should monitor AB 1990 while tightening GLP-1 supplier diligence, COA tracking, bulk-substance documentation, pharmacy contracts, product-quality representations, and patient-facing sourcing claims.
ProposedHigh Impact
California AB575 would require anti-obesity medication and behavioral therapy coverage
California AB575, the Obesity Prevention Treatment Parity Act, would require certain health plans and insurance policies to cover at least one FDA-approved anti-obesity medication and intensive behavioral therapy for obesity treatment without prior authorization.
Operator impact: California clinics should monitor AB575 because coverage mandates without prior authorization would materially change branded GLP-1 access, consult volume, payer workflows, and cash-pay conversion strategy.
ProposedMedium Impact
California SB1089 would allow large employers to negotiate GLP-1 discounts directly
California SB1089 would authorize employers with 100 or more employees to negotiate directly with drug manufacturers for GLP-1 or GLP-1RA discounts.
Operator impact: California clinics should watch employer-direct GLP-1 purchasing because it could create new B2B partnerships, workplace weight-management programs, and hybrid cash-pay plus employer-subsidized pathways.
ProposedMedium Impact
California patient-data advertising watch opened
California is queued for ongoing review around patient data, tracking pixels, consent language, and lead-generation handoffs.
Operator impact: Review landing pages, analytics tags, CRM automations, consent capture, and vendor data flows before scaling paid traffic.
ProposedHigh Impact
California OHCA AB 1415 proposed regulations create MSO and investor filing watch item
California OHCA released proposed AB 1415 implementation revisions affecting private equity groups, hedge funds, MSOs, and other noticing entities, with informal comments open through June 11, 2026.
Operator impact: California-facing clinic platforms should track final OHCA regulations because filing triggers, transaction materiality thresholds, MSO definitions, and notice contents may directly affect acquisition, recapitalization, and MSO structuring timelines.
EffectiveHigh Impact
California restricts PE and hedge fund interference with physician and dental judgment
California SB 351 prohibits private equity groups and hedge funds involved with physician or dental practices from interfering with professional judgment or exercising control over specified clinical and business functions.
Operator impact: California MSO, investor-backed, and rollup models should review control rights, employment decisions, clinical protocols, coding and billing authority, record ownership, equipment approvals, and restrictive covenants.
EffectiveHigh Impact
California AB 1415 expands OHCA oversight to MSOs and transaction notice entities
California AB 1415 expands Office of Health Care Affordability oversight by adding MSO-related data and transaction notice requirements for certain entities.
Operator impact: MSOs, private equity groups, hedge funds, and healthcare rollups with California exposure should review transaction thresholds, notice timing, governance changes, and data-submission obligations before deals close.
EffectiveHigh Impact
California AB 1415 expands OHCA transaction oversight to MSOs and investor entities
California AB 1415 became effective January 1, 2026 and expands Office of Health Care Affordability oversight for certain health care transactions involving private equity groups, hedge funds, MSOs, and related noticing entities.
Operator impact: California MSOs, med spa platforms, DPC groups, concierge groups, telehealth groups, and rollups should review whether transactions, ownership changes, or management arrangements trigger OHCA notice obligations.
EffectiveHigh Impact
California prohibits AI from implying licensed health professional status
California AB 489 makes health-profession license-title restrictions enforceable against AI and GenAI systems that imply care, advice, reports, or assessments are provided by a licensed natural person when they are not.
Operator impact: California clinics and vendors should audit AI chatbot names, voice-agent scripts, disclaimers, sales copy, intake flows, AI-generated assessments, and patient-facing automation to avoid implying a bot is a licensed clinician.
EffectiveHigh Impact
California increases physician-to-PA supervision ratio to 1:8
California AB 1501 increases the number of physician assistants a physician may supervise at one time from four to eight across practice settings.
Operator impact: California cash-pay clinics should reassess PA staffing capacity, supervision documentation, delegation protocols, service-line coverage, and medical director bandwidth under the expanded ratio.
EffectiveHigh Impact
California SB 243 creates companion chatbot safeguards
California SB 243 regulates companion chatbot platforms and requires clear disclosures and safety safeguards when users may believe they are interacting with a human.
Operator impact: California clinics using companion-style wellness bots, mental health support bots, chronic-care check-in bots, or AI health coaches should review disclosures, youth safeguards, self-harm escalation, reporting duties, and human handoff design.
EffectiveHigh Impact
California AB 45 restricts health care facility geofencing and health-location data use
California AB 45 prohibits certain geofencing and personal-information use around in-person health care service locations.
Operator impact: California clinics, agencies, and lead vendors should review location-based advertising, competitor conquesting, facility geofencing, retargeting, location data vendors, and reproductive or gender-affirming care campaign workflows.
EffectiveHigh Impact
Medi-Cal ends GLP-1 coverage for weight-loss-only indications
Medi-Cal Rx materials state that GLP-1 drugs for weight loss only are no longer covered as of January 1, 2026, while some drugs remain covered for other qualifying diagnoses.
Operator impact: California clinics should expect more cash-pay demand, appeals questions, branded-drug navigation needs, and continuity-of-care issues from patients losing obesity-only GLP-1 coverage.
EffectiveHigh Impact
California Farmakeio order highlights peptide bulk and interstate shipping risk
California Board of Pharmacy action involving Farmakeio cited peptide bulk-substance and compounding issues, including BPC-157 acetate, Selank acetate, Semax acetate, and MK-677 products shipped or documented in California-related records.
Operator impact: California-facing clinics and out-of-state pharmacies should review nonresident pharmacy permits, sterile compounding permits, 503A status, shipping records, patient-state licensure, and provider licensure before sending peptide products into California.
EffectiveMedium Impact
California chiropractic accusation highlights stem-cell therapy scope and notice risk
California Board of Chiropractic Examiners accusation materials referenced stem cell therapy definitions, HCT/Ps, and regenerative treatment-related compliance issues.
Operator impact: Chiropractic-med spa hybrids, regenerative referral shops, and wellness clinics should review scope-of-practice, medical director relationships, ownership/control, patient notices, and whether non-physician providers are participating in regenerative medicine beyond their authority.
EffectiveHigh Impact
California requires GenAI notice for patient clinical communications
California AB 3030 requires certain health facilities, clinics, physician offices, and group practices to notify patients when using generative AI to communicate patient clinical information, unless a licensed or certified human reviews the communication.
Operator impact: California clinics using AI agents, AI-generated patient education, automated clinical follow-up, SMS/email clinical communication, chatbots, or voice workflows should review notice language, human review pathways, and escalation procedures.
EffectiveHigh Impact
California AB 352 strengthens reproductive health information privacy
California AB 352 amended health information rules to strengthen privacy protections for reproductive health information and related medical information sharing.
Operator impact: California women’s health, fertility, hormone, telehealth, and primary care clinics should review EHR segmentation, information-sharing settings, out-of-state records requests, patient authorization, and reproductive health data workflows.
EffectiveMedium Impact
California disciplinary record flags deceptive peptide guides and catalogs
California Board of Pharmacy disciplinary records involving Tailormade Compounding alleged deceptive peptide guide and catalog content for substances including BPC-157, CJC-1295, PT-141, Thymosin Alpha-1, and Thymosin Beta-4.
Operator impact: Clinics and pharmacies should treat peptide education pages, protocol PDFs, provider sales decks, and website catalogs as advertising risk assets requiring evidence review and claim substantiation.
EffectiveHigh Impact
California stem cell disclosure law requires notice for non-FDA-approved stem cell therapy
California Business and Professions Code § 684 requires licensed practitioners performing non-FDA-approved stem cell therapy to provide specified notices to patients.
Operator impact: California clinics should verify stem-cell notices are posted, displayed, and provided in writing before initial treatment, and should avoid treating disclosure compliance as authorization to market unapproved regenerative products broadly.
EffectiveHigh Impact
DEA and HHS extend controlled-substance telehealth flexibilities through 2026
DEA and HHS extended telemedicine flexibilities allowing controlled-medication prescribing without a prior in-person visit, when conditions are met, through December 31, 2026.
Operator impact: TRT, ketamine, psychiatry, and other controlled-substance cash-pay models should treat 2026 as a compliance-hardening window before permanent rules are finalized.
Effective Jan 1, 2026
Deadline Dec 31, 2026
DeadlineHigh Impact
FDA PCAC scheduled to review DSIP, Semax, and Epitalon
FDA's Pharmacy Compounding Advisory Committee is scheduled to review Emideltide/DSIP, Semax, and Epitalon-related bulk drug substances for potential 503A bulks list inclusion on July 24, 2026.
Operator impact: Clinics marketing peptides for sleep, cognition, migraine, recovery, or neuro-optimization should review substance-specific claims and avoid implying that PCAC review means FDA approval or immediate lawful compounding access.
Effective Jul 24, 2026
Deadline Jul 24, 2026
DeadlineHigh Impact
FDA PCAC scheduled to review BPC-157, KPV, TB-500, and MOTs-C
FDA's Pharmacy Compounding Advisory Committee is scheduled to review BPC-157, KPV, TB-500, and MOTs-C-related bulk drug substances for potential 503A bulks list inclusion on July 23, 2026.
Operator impact: Peptide clinics, med spas, compounding pharmacies, and wellness prescribers should avoid treating the meeting as approval; review patient claims, current sourcing, substance-by-substance status, pharmacy documentation, and backup offer architecture before changing access language.
Effective Jul 23, 2026
Deadline Jul 23, 2026
PendingMedium Impact
CMS Medicare GLP-1 Bridge scheduled to begin July 1, 2026
CMS announced the Medicare GLP-1 Bridge, a short-term demonstration providing eligible Medicare Part D beneficiaries access to certain GLP-1 drugs from July 1, 2026 through December 31, 2027.
Operator impact: Cash-pay weight-loss clinics should watch Medicare GLP-1 access changes because improved branded-drug access may shift patient expectations, pricing pressure, and referral pathways.
Effective Jul 1, 2026
Deadline Jul 1, 2026
